Fred Hutch's Paulovich lab to lead protein assay work for Beau Biden Cancer Moonshot

February 06, 2017

The Applied Proteogenomics OrganizationaL Learning and Outcomes (APOLLO) network, which is a partnership among the National Cancer Institute (NCI), Department of Defense, and Department of Veterans Affairs, has tapped the Paulovich Laboratory at Fred Hutchinson Cancer Research Center to create a panel of tests to measure key proteins that can serve as markers for tumors. The effort could ultimately lead to treatments that are more specifically targeted to a patient's distinct type of cancer.

The APOLLO network is part of the Cancer Moonshot launched last year and led by former Vice President Joseph Biden. The network is contributing to the initiative's goal of making 10 years of progress in cancer research in just 5 years by using methods in proteogenomics to identify new ways to find and treat cancer. The emerging field of proteogenomics examines how a patient's genes and the proteins the genes produce contribute to cancer growth and response to cancer treatments.

"There's a growing appreciation of the value of proteomic approaches to studying cancer, and how they are complementary to genomic approaches," said Dr. Amanda Paulovich, who is a member of the Fred Hutchinson Cancer Research Center's Clinical Research Division and a professor in the Department of Medicine/Division of Oncology at the University of Washington School of Medicine.

"Genomic profiles alone, while advancing our ability to predict cancer responses to therapy, cannot in many cases provide sufficient information to definitively determine which types of cancers respond best to which therapeutics," Paulovich said. Since most cancer drugs target proteins, the hope is that adding protein analysis to gene analysis will improve the ability to predict tumor response to treatment, and to eventually match the right tumor with the right drug, she said.

"With APOLLO, we believe that by merging our grasp of the genome with a better understanding of its connection to the proteome, or proteogenomics, scientists will have the knowledge, including new regimens and better tools, to assemble the puzzle of precision-based medicine and its translation toward patient care," said Henry Rodriguez, PhD, MBA, director, NCI Office of Cancer Clinical Proteomics Research.

Paulovich's lab is part of NCI's Clinical Proteomic Tumor Analysis Consortium (CPTAC), which was established in 2007 to bring together leading centers nationwide in a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics.

Paulovich's team has pioneered targeted, reproducible proteomic assays that offer significant advantages over traditional laboratory methods for measuring proteins. Established by work spanning over a decade of preclinical testing in the lab of Paulovich and her colleagues, these advantages include standardization across laboratories and the ability to reliably measure many proteins at a time in a sample.

"We're excited to take this technology that we've extensively vetted in preclinical experiments and now begin to implement it in clinical trials," Paulovich said.

Since she joined the research center in 2003, Paulovich has been developing laboratory tests (assays) to measure proteins expressed in human tumors. She and her team have created 249 tests so far, and they have more than 100 additional tests in their pipeline.

Paulovich's proteomics assays are built on a technology called multiple reaction monitoring (MRM) mass spectrometry, which is widely used in clinical chemistry for quantifying smaller molecules (metabolites). It was named the "Method of the Year" for 2012 by the journal Nature Methods.

For protein analysis, the method involves extracting proteins from blood and tissue samples, breaking them up into fragments called peptides, and using specially-designed antibodies to extract peptides of interest for quantification. Then, a specialized piece of laboratory equipment called a mass spectrometer is programmed to select specific peptides, break these up further, and analyze the mass and electrical signals produced by the peptide fragments. Using these signals, the MRM-based assays can detect not only whether a specific protein is present in a blood or tissue sample but how much of it there is, information that could be of vital importance for understanding the biology of a tumor.

APOLLO is initially focusing on lung cancer patients, with plans to eventually include other forms of cancer. Researchers and clinicians will work side-by-side to classify tumors based on molecular changes in genes and in the levels of proteins, and hope ultimately to use that information to devise tests to recommend targeted therapies or refer patients to appropriate clinical trials.

Paulovich's lab will develop a customized panel of MRM-based assays and deploy these assays to quantify tumor proteins in clinical samples from patients receiving treatment. Other collaborators in the Moonshot project will decide on treatments, track how well the treatments shrink the tumors, and then search for correlations that show whether the tumors' protein makeup related to how well the patients responded to treatment.

Paulovich, an oncologist who saw patients before turning to a research career, hopes the work will help to identify new targets for cancer therapeutics and to match patients with cancer therapeutics that are best suited to their conditions.

"Being the physician in the room ordering toxic chemotherapies for my patients and not knowing whether it would do more harm than good, it was a daily ethical dilemma," Paulovich said of her experience working with cancer patients before she came to Fred Hutch.

"I thought I could make a bigger impact by developing translational methods," she said. The protein assays she is creating eventually could become companion diagnostics that oncologists could use when making personalized treatment decisions for their patients.

The Cancer Moonshot aims to speed up the discovery and delivery of cancer prevention, diagnosis and treatment approaches. The initiative is led by NCI and former Vice President Biden who visited the Hutch last summer as part of a tour of the nation's top cancer research centers.
-end-
At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch's pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer with minimal side effects. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation's first and largest cancer prevention research program, as well as the clinical coordinating center of the Women's Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Private contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs. For more information visit fredhutch.org or follow Fred Hutch on Facebook, Twitter or YouTube.

Fred Hutchinson Cancer Research Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.